Top Qs
Timeline
Chat
Perspective

DLX-159

Pharmaceutical compound From Wikipedia, the free encyclopedia

Remove ads

DLX-159 is a putatively non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and other psychiatric disorders.[1][3][2] It is taken by mouth.[1][2]

Quick Facts Clinical data, Other names ...
Remove ads

Pharmacology

Summarize
Perspective

The full mechanism of action of DLX-159 has yet to be disclosed.[1][2] The drug shows psychoplastogenic effects in vitro and ex vivo.[2] These effects are blocked by the serotonin 5-HT2A receptor antagonst ketanserin as well as by the mTOR inhibitor rapamycin.[2] It also shows indications of psychoplastogenic effects in vivo in rodents.[2] In addition, similarly to ketamine, DLX-159 shows rapid antidepressant-like effects in the forced swim test (FST) in rodents that are present within 24 hours of a single dose and are sustained for at least 3 days.[2] DLX-159 also reversed the depression-like phenotype induced by chronic interferon alpha exposure in rodents.[2] DLX-159 does not produce the head-twitch response, and hence does not appear to have psychedelic effects.[2]

DLX-159 shows no signs of cardiotoxicity in preclinical studies.[2] It was assessed at the serotonin 5-HT2B receptor and was found to be an antagonist of this receptor.[2] It is said that further data on the pharmacological activity of DLX-159, including its activities at various receptors and enzymes, will be published in the future.[2] The drug is orally bioavailable and crosses the blood–brain barrier.[2]

Remove ads

Research

DLX-159 is under development by Delix Therapeutics.[1][3][2] As of January 2025, it is in the preclinical research stage of development.[1][3] The drug was first described in the scientific literature by December 2024.[2] Its chemical structure does not yet seem to have been disclosed.[1]

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads